Drug discovery is either an exact business that is based on detailed knowledge of target structure or it is a fishing expedition that uncovers new drugs through screening of random compounds for their biological effect on target function. Isolation of a new p53 activator with anticancer properties strengthens the reputation of this second approach (pages 1321–1328).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Issaeva, N. et al. Nat. Med. 10, 1321–1328 (2004).
Fischer, P.M. & Lane, D.P. Trends Pharmacol. Sci. 25 343–346 (2004).
Vassilev, L.T. et al. Science 303, 844–848 (2004).
Bykov, V.J. et al. Nat. Med. 8, 282–288 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gudkov, A. Cancer drug discovery: the wisdom of imprecision. Nat Med 10, 1298–1299 (2004). https://doi.org/10.1038/nm1204-1298
Issue Date:
DOI: https://doi.org/10.1038/nm1204-1298
This article is cited by
-
HIV Preclinical–Clinical Therapeutics Research: Central Nervous System Approaches
Journal of Neuroimmune Pharmacology (2007)
-
Syrrx acquisition signals maturation of structure-based discovery
Nature Biotechnology (2005)
-
Reviews and comment from the nature publishing group
Nature Reviews Cancer (2005)
-
Reviews and comment from the nature publishing group
Nature Reviews Drug Discovery (2005)
